Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for Viridian Therapeutics in a report issued on Tuesday, May 6th. Wedbush analyst L. Chico now expects that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($1.04). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. Wedbush also issued estimates for Viridian Therapeutics' Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.25) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($3.10) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $5.43 EPS and FY2029 earnings at $8.81 EPS.
A number of other research analysts also recently commented on the company. Needham & Company LLC reduced their price target on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group reduced their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Royal Bank of Canada reduced their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $36.70.
Read Our Latest Stock Analysis on VRDN
Viridian Therapeutics Stock Down 2.4%
VRDN traded down $0.31 on Friday, reaching $12.81. The company's stock had a trading volume of 869,767 shares, compared to its average volume of 1,194,846. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -2.97 and a beta of 0.57. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The business's 50 day moving average is $13.66 and its 200 day moving average is $17.37.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. The company's revenue was up .0% compared to the same quarter last year.
Institutional Trading of Viridian Therapeutics
Several hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. lifted its holdings in shares of Viridian Therapeutics by 1.4% in the 1st quarter. Raymond James Financial Inc. now owns 318,240 shares of the company's stock worth $4,290,000 after purchasing an additional 4,453 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Viridian Therapeutics by 8.2% in the 1st quarter. American Century Companies Inc. now owns 122,892 shares of the company's stock worth $1,657,000 after purchasing an additional 9,330 shares during the last quarter. Persistent Asset Partners Ltd lifted its holdings in shares of Viridian Therapeutics by 47.4% in the 1st quarter. Persistent Asset Partners Ltd now owns 37,211 shares of the company's stock worth $502,000 after purchasing an additional 11,974 shares during the last quarter. Knott David M Jr lifted its holdings in shares of Viridian Therapeutics by 20.0% in the 1st quarter. Knott David M Jr now owns 30,000 shares of the company's stock worth $404,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of Viridian Therapeutics in the 1st quarter worth approximately $3,352,000.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
